Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL
about
Idelalisib for the treatment of chronic lymphocytic leukemiaRichter's transformation to diffuse large B-cell lymphoma: a retrospective study reporting clinical data, outcome, and the benefit of adding rituximab to chemotherapy, from the Israeli CLL Study Group.Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapyB-cell receptor signaling as a driver of lymphoma development and evolution.BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.B cell receptor signaling in chronic lymphocytic leukemia.
P2860
Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL
@ast
Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL
@en
type
label
Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL
@ast
Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL
@en
prefLabel
Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL
@ast
Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL
@en
P2860
P356
P1476
Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL
@en
P2093
Adrian Wiestner
Luca Laurenti
P2860
P304
P356
10.4084/MJHID.2012.067
P577
2012-10-09T00:00:00Z